Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

MB310 has been developed as an oral capsule, dosed once daily, containing a defined consortium of eight live gut commensal ...

Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...

Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with ...

Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.

Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate to severe UC patients.

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

Local philanthropists Larry Sears and Sally Zlotnick Sears awarded a “transformative” $1 million gift to the Crohn’s & ...

Johnson & Johnson announced data from the Phase 3 ASTRO study of TREMFYA subcutaneous, SC, induction therapy in adults with moderately to ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...

Teva (TEVA) stock and Alvotech (ALVO) stock in focus as duo launches Selarsdi, a biosimilar to J&J's (JNJ) Stelara after a ...